Expression and clinical significance of apoptotic protease activating factor 1 and bax in prostate cancer
10.3760/cma.j.issn.1006-9801.2016.02.011
- VernacularTitle:前列腺癌组织凋亡蛋白酶活化因子1和bax的表达及其临床意义
- Author:
Bingxin ZHANG
;
Xia ZHAO
;
Jinku ZHANG
;
Wenwen JIA
;
Jianshu ZHANG
;
Jianmei SUN
;
Xihua JIA
- Publication Type:Journal Article
- Keywords:
Prostatic neoplasms;
Benign prostatic hyperplasia;
Apoptotic protease activating factor 1;
Bax
- From:
Cancer Research and Clinic
2016;28(2):116-118
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the expression and clinical significance of apoptotic protease activating factor 1 (Apaf-1) and bax in prostate cancer (PCa) and benign prostatic hyperplasia (BPH). Methods Immunohistochemistry was used to detect the expression of Apaf-1 and bax in the tissues from 45 PCa patients and 60 BPH patients. Results The positive rates of Apaf-1 and bax in PCa tissues were 22.22%(10/45) and 20.00 % (9/45), respectively, while those in BPH tissues were 48.33 % (29/60) and 46.67 % (28/60). There was a statistically significant difference in the expressions of Apaf-1 and bax between two groups (P< 0.05). The expressions of Apaf-1 and bax were not correlated with the age of patients and distant metastasis (P>0.05), but they were correlated with the pathological grade and clinical stage of PCa (P< 0.05). The expressions of Apaf-1 and bax in PCa tissues were lower than those in BPH tissues. There was a positive correlation between the expression of Apaf-1 and bax (r=0.535, P<0.01). Conclusion Apaf-1 and bax might be correlated with the carcinogenesis and development of PCa.
